Research
Is weekly or daily atropine more effective for pediatric myopia management?
Weekly 1% atropine drops may be a potentially effective treatment in younger and mildly myopic patients.
Research
Atropine 0.05% for myopia shows promise in 5-year LAMP study
Extended data builds on prior 1-year and 3-year findings regarding atropine effectiveness for childhood myopia.
Research
Atropine efficacy may be influenced by race, eye color
Study may shed light on how atropine effects differ among certain population characteristics.
Research
Low-dose atropine study in myopic pediatrics contradicts prior research
Randomized, U.S.-based trial reveals surprising lack of efficacy for atropine, 0.01%
Research
Ortho-k and atropine combo may slow pediatric myopia
Combination therapy demonstrated significant reduction in axial length elongation for the first 1.5 years of treatment.
Research
Low-dose atropine shows benefits for pediatric myopia progression
New study supports the use of 0.01% atropine eye drops (NVK002).
Research
Nightly atropine may lead to lower incidence of myopia
New study finds 0.05% atropine eye drops has the potential to significantly reduce fast myopic shift.
Products
Harrow launches next-gen atropine formulations
Patent-pending, compounded formulation is available in three concentrations.
Research
Study finds atropine has negative effects post-glaucoma surgery
Patients report a reduction in visual quality following trabeculectomy.
Research
National trial to test preventative atropine drops for pediatric myopia
The University of Houston and The Ohio State University researchers partner on NEI-funded study to test if low-concentrated drops delay onset of myopia.
Pipeline
FDA accepts NDA for Sydnexis's low-dose atropine for pediatric myopia
Once-daily drop features unique establishing excipient to avoid rapid atropine degradation; may become first eye drop with 3-year shelf-life.
Archives
New FDA approval for a diabetic retinopathy screening tool. — Weekly Glance
AEYE Health has received FDA clearance to market its diagnostic screening system for diabetic retinopathy.
Pipeline
iVeena submits IND to FDA for pediatric myopia clinical trial
Company plans to initiate a multinational phase 2 study on IVMED-85, a PF and non-atropine daily eye drop intended to improve refraction and decrease AE rates.
Pipeline